David Fiorentino, MD
Enriched profileProfessor of Dermatology, with courtesy appointments in Immunology and Rheumatology · Stanford University School of Medicine
David Fiorentino is Professor of Dermatology, with courtesy appointments in Immunology and Rheumatology at Stanford University School of Medicine. OpenAlex indexes 256 publications with 24,837 citations (h-index 67); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Dermatology profiles in the findmyKOL directory.
Data verified 13 Oct 2026
Overview
Updated 14 Oct 2026
David Fiorentino, MD, is Professor of Dermatology, with courtesy appointments in Immunology and Rheumatology at Stanford University School of Medicine. The public record shows 256 publications with 24,837 citations (h-index 67), centered on Systemic Sclerosis and Related Diseases, Inflammatory Myopathies and Dermatomyositis, Myasthenia Gravis and Thymoma. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2006–2007).
- Most recent indexed publication: 2026 · The Journal of rheumatology
- Top research focus: Systemic Sclerosis and Related Diseases
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 139.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Sponsor: Stanford University
- Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
Sponsor: Wright State University
Industry payments
Updated 14 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20253 payments
- Legend Biotech USA Inc.Program year20251 payment
- UCB SAProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
41.4%Corticosteroid41.4%Prednisone100%Part D<11 patientsCancer & immunology
32.8%Folate Analog Metabolic Inhibitor21.6%Methotrexate100%Part D<11 patientsThalidomide Analog11.2%Lenalidomide100%Part D<11 patientsSensory organs
13.8%Corticosteroid13.8%Clobetasol Propionate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2006–2007 per NIH RePORTER. The latest:
- Interferons and cytotoxic lymphocytes in dermatomyositis and cutaneous lupus
Johns Hopkins University
FY2013$200,001R56AR062615 - MULTIPLE DOSES OF TRX1 (ANTI-CD4 MAB) WHEN ADMINISTERED BY INTRAVENOUS INFUSION
Stanford University
FY2007$14,628M01RR000070 - RITUXIMAB IN THE TREATMENT OF PATIENTS WITH DERMATOMYOSITIS
Stanford University
FY2007$8,193M01RR000070
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies.
The Journal of rheumatology
Clinical Trial2026 - Primary Cutaneous Gamma-Delta T-Cell Lymphoma Complicating Long-Standing Immunosuppressed Dermatomyositis.
Journal of cutaneous pathology
Case Report2026 - Artificial Intelligence-Aided Lung Ultrasound Detection of Interstitial Lung Disease in Systemic Sclerosis and Inflammatory Myopathy.
Arthritis care & research
Article2026 - Identification of Adult Patients With Dermatomyositis Using Real-World Data Sources.
Arthritis care & research
Article2026 - Validation of Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease in Systemic Sclerosis and Inflammatory Myopathy.
Arthritis care & research
Article2025
Most-cited works
by citation count (OpenAlex)- 01IL-10 inhibits cytokine production by activated macrophagesArticle2,890 citations1991
- 02
- 03IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cellsArticle1,865 citations1991
- 04Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFIArticle1,143 citations1990
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Founding member and past president
Rheumatologic Dermatology Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Awards & honors
honors on the public record- 2024 Research Achievement Award in Autoimmune & Inflammatory Skin Disorders and Vitiligo
American Skin Association
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →americanskin.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Secondary affiliations
appointments beyond the home institution- Member
Bio-X at Stanford
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →openminds.stanford.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Heidenreich, MD
Stanford University School of Medicine
Alan Schatzberg, MD
Stanford University School of Medicine
Euan Ashley, MD
Stanford University School of Medicine
Mark Pegram, MD
Stanford University School of Medicine
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania